Treatment with epoprostenol and low-molecular-weight heparin during pregnancy in 3 women with pulmonary arterial hypertension resulted in uneventful deliveries and no postpartum complications.
Case Report (n=3)
Does epoprostenol and low-molecular-weight heparin therapy allow successful pregnancy completion in patients with pulmonary arterial hypertension?
Stable patients with pulmonary arterial hypertension on epoprostenol and low-molecular-weight heparin may successfully complete pregnancy, although it remains high risk.
BACKGROUND: Pregnancy is contraindicated in cases of pulmonary hypertension, a highly morbid disease affecting young women of childbearing age. CASES: We describe the pregnancies of 3 patients with pulmonary arterial hypertension (idiopathic, Eisenmenger syndrome, and related to systemic lupus erythematosus). They received epoprostenol and low-molecular-weight heparin throughout pregnancy. The patient with Eisenmenger syndrome started epoprostenol in gestational week 16. Cesarean delivery under general anesthesia was performed at 28-33 weeks of gestation; early delivery was necessary in the patient with Eisenmenger syndrome because of fetal growth restriction. All deliveries were uneventful, and birth weights were 1,700, 1,500, and 795 g. There were no postpartum complications. CONCLUSION: Pregnancy in women with pulmonary hypertension should still be considered high risk for both mother and child, but stable patients on epoprostenol may successfully complete pregnancy.
Bendayan et al. (Tue,) conducted a case report in Pulmonary arterial hypertension in pregnancy (n=3). Epoprostenol and low-molecular-weight heparin was evaluated on Pregnancy outcomes (delivery success, birth weight, postpartum complications). Treatment with epoprostenol and low-molecular-weight heparin during pregnancy in 3 women with pulmonary arterial hypertension resulted in uneventful deliveries and no postpartum complications.